XBI
·ARCA
--
--(--)
--
--(--)
Key Stats
Assets Under Management
7.69BUSD
Fund Flows (1Y)
-339.70MUSD
Dividend Yield
0.03%
Discount/Premium to NAV
0.03%
Shares Outstanding
64.75M
Expense Ratio
0.35%
About State Street SPDR S&P Biotech ETF
Issuer
State Street Global Advisors
Brand
SPDR
Inception Date
Jan 31, 2006
Structure
Open-Ended Fund
Index Tracked
S&P Biotechnology Select Industry Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
SSgA Funds Management, Inc.
Distributor
State Street Corp. (Fund Distributor)
XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Biotechnology
Strategy
Equal
Geography
U.S.
Weighting Scheme
Equal
Selection Criteria
Market cap
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | +6.55% | +27.59% | +32.97% | +28.69% | +47.43% | -16.60% |
NAV Total Return | +7.10% | +27.57% | +33.38% | +25.96% | +49.94% | -13.79% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region
96.19%
3.81%
Category
Ratio
North America
96.19%
Europe
3.81%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Multi-Cap Growth
Comprises companies of multiple sizes that have high growth potential. These ETFs focus on firms across different market caps with promising growth prospects.
Top 10 Holdings
Symbol
Ratio
EXAS
Exact Sciences
2.85%
RVMD
Revolution Medicines
2.71%
RNA
Avidity Biosciences
2.38%
BBIO
BridgeBio Pharma
2.16%
REGN
Regeneron
2.08%
INSM
Insmed
2.07%
NTRA
Natera
2.06%
MDGL
Madrigal
2.00%
PRAX
Praxis
1.98%
ROIV
Roivant Sciences
1.96%
Top 10 Weight 22.24%
135 Total Holdings
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2025-09-22 | 2025-09-22 | 2025-09-24 | 0.027 |
| 2025-06-23 | 2025-06-23 | 2025-06-25 | 0.007 |
| 2025-03-24 | 2025-03-24 | 2025-03-26 | 0.005 |
| 2024-12-23 | 2024-12-23 | 2024-12-26 | 0.003 |
| 2024-09-23 | 2024-09-23 | 2024-09-25 | 0.015 |
| 2024-06-24 | 2024-06-24 | 2024-06-26 | 0.115 |
| 2023-12-18 | 2023-12-19 | 2023-12-21 | 0.014 |
Show more
Premium/Discount Chart
Premium/Discount to NAV
Price
1M
Assets Under Management
Assets Under Management
1M
Fund Flows
Inflows
Outflows
1M
